Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 3/20 | 0.40 |
| ▸ | GABRG2 | P18507 | 3/20 | 0.40 |
| ▸ | GABRB3 | P28472 | 3/20 | 0.40 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.40 |
| ▸ | MMP13 | P45452 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | APEX1 | P27695 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | MMP2 | P08253 | 4/20 | 0.35 |
| ▸ | MMP9 | P14780 | 4/20 | 0.35 |
| ▸ | MMP3 | P08254 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phenobarbital SCHEMBL11114624 | 0.81 | KMT2A (0.51) | MMP13LMNAKMT2AMEN1CYP1A2 | |
| SCHEMBL715099 | 0.77 | MMP9 (0.51) | GABRA1GABRG2GABRB3GABRB2MMP13 | |
| SCHEMBL32689845 | 0.75 | KMT2A (0.42) | GABRA1GABRG2GABRB3GABRB2MMP13 | |
| SCHEMBL23959035 | 0.72 | LMNA (0.51) | GABRA1GABRG2GABRB3GABRB2LMNA | |
| Allobarbital SCHEMBL3642549 | 0.72 | MMP2 (0.47) | GABRA1GABRG2GABRB3GABRB2MMP13 | |
| Allobarbital SCHEMBL15364694 | 0.72 | KDM4E (0.31) | LMNA | |
| SCHEMBL4379252 | 0.72 | LMNA (0.46) | LMNAKMT2AMEN1CYP1A2POLB | |
| Phenobarbital SCHEMBL7618451 | 0.71 | MMP9 (0.63) | GABRA1GABRG2GABRB3GABRB2MMP13 | |
| SCHEMBL4038790 | 0.69 | AKR1B1 (0.36) | LMNAKMT2AMEN1CYP1A2POLB | |
| SCHEMBL8676257 | 0.69 | GAA (0.38) | GABRA1GABRG2GABRB3GABRB2MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12161695-B2 | GABA A receptor agonists for treatment of disorders influenced by dysfunction BETA cells | DIAMYD MEDICAL AB (SE) | 2024-12-10 | — | — | US | claimed |
| US-20210113586-A1 | NEW USE AND METHODS OF MODULATING IMMUNE RESPONSES | DIAMYD MEDICAL AB (SE) | 2021-04-22 | — | — | US | claimed |
| EP-3755314-A1 | GABA A RECEPTOR AGONISTS FOR TREATMENT OF DISORDERS INFLUENCED BY DYSFUNCTION BETA CELLS | Diamyd Medical AB (SE) | 2020-12-30 | — | — | EP | claimed |
| EP-3756007-A1 | NEW USE AND METHODS OF MODULATING IMMUNE RESPONSES | Diamyd Medical AB (SE) | 2020-12-30 | — | — | EP | claimed |
| US-20200384086-A1 | GABA A RECEPTOR AGONISTS FOR TREATMENT OF DISORDERS INFLUENCED BY DYSFUNCTION BETA CELLS | DIAMYD MEDICAL AB (SE) | 2020-12-10 | — | — | US | claimed |
| US-20200138830-A1 | ENHANCING GABA'S ABILITY TO MODULATE IMMUNE RESPONSES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-05-07 | — | — | US | claimed |
| EP-3642206-A1 | ENHANCING GABA'S ABILITY TO MODULATE IMMUNE RESPONSES | The Regents of The University of California (US) | 2020-04-29 | — | — | EP | claimed |
| WO-2019162403-A1 | GABA A RECEPTOR AGONISTS FOR TREATMENT OF DISORDERS INFLUENCED BY DYSFUNCTION BETA CELLS | DIAMYD MEDICAL AB (SE) | 2019-08-29 | — | — | WO | claimed |
| WO-2019164446-A1 | NEW USE AND METHODS OF MODULATING IMMUNE RESPONSES | DIAMYD MEDICAL AB (SE) | 2019-08-29 | — | — | WO | claimed |
| WO-2018236955-A1 | ENHANCING GABA'S ABILITY TO MODULATE IMMUNE RESPONSES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-12-27 | — | — | WO | claimed |
| US-20180235916-A1 | ENHANCING BETA CELL REPLICATION AND/OR SURVIVAL | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-08-23 | — | — | US | claimed |
| EP-3362069-A1 | ENHANCING BETA CELL REPLICATION AND/OR SURVIVAL | The Regents of The University of California (US) | 2018-08-22 | — | — | EP | claimed |
| US-20170296532-A1 | COMPOSITIONS FOR CONTROL OF DRUG ABUSE | KYDES PHARMACEUTICALS (US) | 2017-10-19 | — | — | US | claimed |
| WO-2017066240-A1 | ENHANCING BETA CELL REPLICATION AND/OR SURVIVAL | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-04-20 | — | — | WO | claimed |
| US-20130295170-A1 | COMPOSITIONS FOR CONTROL OF DRUG ABUSE | KYDES PHARMACEUTICALS LLC (US) | 2013-11-07 | — | — | US | claimed |
| US-12161695-B2 | GABA A receptor agonists for treatment of disorders influenced by dysfunction BETA cells | DIAMYD MEDICAL AB (SE) | 2024-12-10 | — | — | US | disclosed |
| US-11992495-B2 | Enhancing GABA's ability to modulate immune responses | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-05-28 | — | — | US | disclosed |
| EP-2120871-A1 | LINKER-BASED LECITHIN MICROEMULSION DELIVERY VEHICLES | Acosta-Zara, Edgar, Joel (CA) | 2009-11-25 | — | — | EP | disclosed |
| WO-2008070961-A1 | LINKER-BASED LECITHIN MICROEMULSION DELIVERY VEHICLES | ACOSTA-ZARA EDGAR JOEL (CA) | 2008-06-19 | — | — | WO | disclosed |
| US-20080139392-A1 | Linker-Based Lecithin Microemulsion Delivery Vehicles | ACOSTA-ZARA EDGAR JOEL | 2008-06-12 | — | — | US | disclosed |